11
Participants
Start Date
December 10, 2013
Primary Completion Date
August 26, 2025
Study Completion Date
August 26, 2025
Regorafenib
All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center Sleepy Hollow, Sleepy Hollow
Downstate Medical Center, Brooklyn
Queens Cancer Center of Queens Hospital, Jamaica
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre
Memorial Sloan Kettering Cancer Center at Commack, Commack
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge
Collaborators (1)
Bayer
INDUSTRY
State University of New York - Downstate Medical Center
OTHER
Queens Cancer Center of Queens Hospital
OTHER
Memorial Sloan Kettering Cancer Center
OTHER